Alzheimer?s disease is a progressive neurodegenerative disorder with no effective treatment. The only FDA-approved medications are cholinesterase inhibitors (AChEIs), developed based on the Alzheimer?s cholinergic hypothesis. However, AChEI therapy is a modest symptomatic treatment, and no improvement has been made in the last 15 years due to lack of understanding of cholinergic transmission in Alzheimer?s patients. Our parent grant aims to develop and validate families of genetically-encoded acetylcholine (ACh) sensors with sensitivity, specificity, signal-to-noise ratio, kinetics and photostability suitable for monitoring ACh signals in vitro and in vivo. While validating our newly generated ACh sensors, our experiments unveiled a few fundamental, yet unexpected properties of central cholinergic transmission, including the firing pattern-dependent release, restricted volume transmission with subcellular precision and ultra-low release probability. These preliminary results immediately provide an explanation for the low efficacy of current Alzheimer?s medications and point out new effective intervention options for Alzheimer?s disease. In this supplemental application, I propose to interrogate cholinergic transmission in both normal and Alzheimer?s brains following one specific aim, that is to visualize normal and Alzheimer?s cholinergic transmissions. Our plan is to interrogate central cholinergic transmission in the juvenile, adult and aged wild type mice (Aim 1a). Moreover, we will investigate central cholinergic transmission in the juvenile, adult and aged SAMP8 mice, a robust model for sporadic Alzheimer?s disease, as well as in familial Alzheimer's disease animal models, including Tg2576 and/or APP/PS1 mice (Aim 1b). We expect these experiments to characterize cholinergic transmission at different ages in normal brains and reveal how cholinergic transmission may be altered in Alzheimer?s brains.

Public Health Relevance

Despite its significance in developing effective therapy, our understanding of cholinergic transmission in Alzheimer?s brains remains lagged behind due primarily to the limitations of tools available for monitoring acetylcholine in brains. We propose to use our newly developed families of genetically-encoded acetylcholine sensors to study cholinergic transmission in normal and Alzheimer?s brains, and expect the findings to point out new effective intervention options for Alzheimer?s disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS104670-01S1
Application #
9705114
Study Section
Program Officer
Churn, Severn Borden
Project Start
2017-12-01
Project End
2022-11-30
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Virginia
Department
Pharmacology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Zhang, Lei; Zhang, Peng; Wang, Guangfu et al. (2018) Ras and Rap Signal Bidirectional Synaptic Plasticity via Distinct Subcellular Microdomains. Neuron 98:783-800.e4
Jing, Miao; Zhang, Peng; Wang, Guangfu et al. (2018) A genetically encoded fluorescent acetylcholine indicator for in vitro and in vivo studies. Nat Biotechnol 36:726-737